How taXonomy Pathways builds comprehensive patient journeys
In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic...
In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic...
When we introduced HealthVerity eXOs, an agentic AI platform powered by Medeloop, in our recent...
The evolution of heart failure treatment and research Heart failure remains one of the most...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
At HealthVerity, community is at the heart of who we are. Each year, our team members come together...
AI agents are quickly becoming part of the clinical conversation. Since the release of large...
We put the newest HealthVerity eXOs capabilities to the test on one of the most-watched questions in healthcare: who is starting GLP-1s, where they are and what happens next. Here is what the new features did and what the data revealed.